SEOUL, South Korea, Feb. 13, 2025 /PRNewswire/ — DAAN Biotherapeutics, a leading innovative drug development company specializing in T-cell receptor (TCR)- based therapies, has signed an exclusive licensing agreement with LigaChem Biosciences for a novel tumor-targeting antibody to advance the development and commercialization of Antibody-Drug Conjugates (ADC).
By leveraging DAAN Biotherapeutics’ next-generation antibody technology, built upon its exceptional target discovery and antibody development capabilities, LigaChem Biosciences is now positioned to take a significant step forward in ADC development for solid tumor patients.
DAAN Biotherapeutics has successfully established a proprietary pipeline for efficiently developing antibodies targeting overexpressed tumor targets in solid cancers through a strategic partnership with OmniAb.
Byoung Chul Cho, MD, the CEO of DAAN Biotherapeutics, stated, “We will continue to develop state-of-the-art antibodies targeting solid tumors and collaborate with global pharmaceutical companies in the ADC field. Beyond ADCs, we also aim to become a global leader in solid tumor-targeting T-cell engagers using our proprietary TACTIC (Tumor Targeting Conditionally Activated T Cell Engager) platform.”
ข่าวที่เกี่ยวข้อง
- AION UT นิยามใหม่แห่งมาตรฐานความปลอดภัยรถยนต์ไฟฟ้าขนาดเล็ก! ขึ้นแท่นความปลอดภัยระดับ 5 ดาว จาก Euro NCAP ประจำปี 2569
- Discover Japanese Suppliers of Pre-Owned Luxury Watches & Jewelry at IJT AUTUMN 2026
- Hyosung Chairman Cho Hyun-Joon targets U.S. AI power market with 22.9kV SST
- CoCo to Exhibit at The National Franchise Show, Highlighting Flexible Partnership Models for Canadian Markets
